Post-earnings recap
Reported
Wed, Feb 16, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that 10X Genomics is facing challenges, particularly reflected in the negative EPS. The stock's slight decline of 0.34% suggests that investors may be reacting to the lack of guidance and the unexpected loss. Overall, the company appears to be prioritizing long-term growth strategies amid current uncertainties.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.16 | N/A | -158.06% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook, emphasizing the importance of long-term strategies. They acknowledged the current difficulties but did not provide specific guidance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company is focusing on long-term growth despite current challenges.